Todd Harris - Mar 29, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Executive Officer, Director
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Mar 29, 2023
Transactions value $
-$59,820
Form type
4
Date filed
3/31/2023, 07:02 PM
Previous filing
Mar 28, 2023
Next filing
Apr 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $3.2K +1.42K +0.08% $2.25* 1.7M Mar 29, 2023 Direct
transaction TYRA Common Stock Sale -$23K -1.42K -0.08% $16.18 1.7M Mar 29, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $5.42K +2.41K +0.14% $2.25* 1.7M Mar 30, 2023 Direct
transaction TYRA Common Stock Sale -$38.6K -2.41K -0.14% $16.02 1.7M Mar 30, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $1.13K +500 +0.03% $2.25* 1.7M Mar 31, 2023 Direct
transaction TYRA Common Stock Sale -$8.02K -500 -0.03% $16.05 1.7M Mar 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -1.42K -0.35% $0.00 402K Mar 29, 2023 Common Stock 1.42K $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2.41K -0.6% $0.00 400K Mar 30, 2023 Common Stock 2.41K $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -500 -0.12% $0.00 400K Mar 31, 2023 Common Stock 500 $2.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.